<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2018-07-06" updated="2019-12-02">
  <drugbank-id primary="true">DB14484</drugbank-id>
  <drugbank-id>DBSALT002423</drugbank-id>
  <name>Magnesium ascorbate</name>
  <description/>
  <cas-number>15431-40-0</cas-number>
  <unii>0N1G678593</unii>
  <average-mass>374.537</average-mass>
  <monoisotopic-mass>374.03356759</monoisotopic-mass>
  <groups>
    <group>approved</group>
    <group>nutraceutical</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Ascorbic acid, magnesium salt</synonym>
    <synonym language="english" coder="">L(+)-ascorbic acid magnesium salt</synonym>
    <synonym language="english" coder="">Vitamin C magnesium salt</synonym>
  </synonyms>
  <products>
    <product>
      <name>EnBrace HR</name>
      <labeller>Jaymac Pharmaceuticals, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>64661-650</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, delayed release pellets</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Energy 80 Prolonged Release Tab</name>
      <labeller>Sportscience Labs Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00543721</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-12-31</started-marketing-on>
      <ended-marketing-on>2002-06-20</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>EnLyte</name>
      <labeller>Jaymac Pharmaceuticals Llc</labeller>
      <ndc-id/>
      <ndc-product-code>64661-711</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, delayed release pellets</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>OB Complete Gold</name>
      <labeller>Vertical Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68025-068</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PramLyte</name>
      <labeller>Allegis Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>28595-400</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-11</started-marketing-on>
      <ended-marketing-on>2016-01-04</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA078604</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>PramLyte</name>
      <ingredients>1,2-Docosahexanoyl-sn-glycero-3-phosphoserine + 1,2-icosapentoyl-sn-glycero-3-phosphoserine + Citric acid + Cobamamide + Cocarboxylase + Escitalopram + Ferrous cysteine glycinate + Flavin adenine dinucleotide + Folic acid + Glycine betaine + Leucovorin + Levomefolic acid + Magnesium ascorbate + NADH + Phosphatidyl serine + Pyridoxal phosphate + Sodium citrate + Zinc ascorbate</ingredients>
    </mixture>
    <mixture>
      <name>OB Complete Gold</name>
      <ingredients>1-(c14-c18 esteroyl)-2-docosahexanoyl-sn-glycero-3-phosphocholine + 1-(c14-c18 esteroyl)-2-docosahexanoyl-sn-glycero-3-phosphoethanolamine + 5-methyltetrahydrofolic acid + Calcium carbonate + Cholecalciferol + Cyanocobalamin + Egg phospholipids + Folic acid + Iron + Magnesium ascorbate + Potassium Iodide + Pyridoxine + Vitamin E</ingredients>
    </mixture>
    <mixture>
      <name>EnLyte</name>
      <ingredients>1,2-Docosahexanoyl-sn-glycero-3-phosphoserine + 1,2-icosapentoyl-sn-glycero-3-phosphoserine + Citric acid + Cobamamide + Cocarboxylase + Ferrous cysteine glycinate + Flavin adenine dinucleotide + Folic acid + Glycine betaine + L-threonic acid + Leucovorin + Levomefolic acid + Magnesium ascorbate + NADH + Phosphatidyl serine + Pyridoxal phosphate + Sodium citrate + Zinc ascorbate</ingredients>
    </mixture>
    <mixture>
      <name>EnBrace HR</name>
      <ingredients>1,2-Docosahexanoyl-sn-glycero-3-phosphoserine + 1,2-icosapentoyl-sn-glycero-3-phosphoserine + Cobamamide + Cocarboxylase + Ferrous cysteine glycinate + Flavin adenine dinucleotide + Folic acid + Glycine betaine + L-threonic acid + Leucovorin + Levomefolic acid + Magnesium ascorbate + NADH + Phosphatidyl serine + Pyridoxal phosphate + Zinc ascorbate</ingredients>
    </mixture>
    <mixture>
      <name>Energy 80 Prolonged Release Tab</name>
      <ingredients>Calcium ascorbate + Cyanocobalamin + Folic acid + Magnesium ascorbate + Pantothenic acid + Pyridoxine</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Compounds used in a research, industrial, or household setting</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Urinary Acidifying Agents</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule, delayed release pellets</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>Magnesium ascorbate may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>Magnesium ascorbate may increase the excretion rate of Mecamylamine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>The serum concentration of Amphetamine can be decreased when it is combined with Magnesium ascorbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00191</drugbank-id>
      <name>Phentermine</name>
      <description>The serum concentration of Phentermine can be decreased when it is combined with Magnesium ascorbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00852</drugbank-id>
      <name>Pseudoephedrine</name>
      <description>The serum concentration of Pseudoephedrine can be decreased when it is combined with Magnesium ascorbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00865</drugbank-id>
      <name>Benzphetamine</name>
      <description>The serum concentration of Benzphetamine can be decreased when it is combined with Magnesium ascorbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00937</drugbank-id>
      <name>Diethylpropion</name>
      <description>The serum concentration of Diethylpropion can be decreased when it is combined with Magnesium ascorbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01255</drugbank-id>
      <name>Lisdexamfetamine</name>
      <description>The serum concentration of Lisdexamfetamine can be decreased when it is combined with Magnesium ascorbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01365</drugbank-id>
      <name>Mephentermine</name>
      <description>The serum concentration of Mephentermine can be decreased when it is combined with Magnesium ascorbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01442</drugbank-id>
      <name>MMDA</name>
      <description>The serum concentration of MMDA can be decreased when it is combined with Magnesium ascorbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01454</drugbank-id>
      <name>Midomafetamine</name>
      <description>The serum concentration of Midomafetamine can be decreased when it is combined with Magnesium ascorbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01467</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylamphetamine</name>
      <description>The serum concentration of 2,5-Dimethoxy-4-ethylamphetamine can be decreased when it is combined with Magnesium ascorbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01484</drugbank-id>
      <name>4-Bromo-2,5-dimethoxyamphetamine</name>
      <description>The serum concentration of 4-Bromo-2,5-dimethoxyamphetamine can be decreased when it is combined with Magnesium ascorbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01509</drugbank-id>
      <name>Tenamfetamine</name>
      <description>The serum concentration of Tenamfetamine can be decreased when it is combined with Magnesium ascorbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01556</drugbank-id>
      <name>Chlorphentermine</name>
      <description>The serum concentration of Chlorphentermine can be decreased when it is combined with Magnesium ascorbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01566</drugbank-id>
      <name>Methylenedioxyethamphetamine</name>
      <description>The serum concentration of Methylenedioxyethamphetamine can be decreased when it is combined with Magnesium ascorbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01576</drugbank-id>
      <name>Dextroamphetamine</name>
      <description>The serum concentration of Dextroamphetamine can be decreased when it is combined with Magnesium ascorbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01577</drugbank-id>
      <name>Metamfetamine</name>
      <description>The serum concentration of Metamfetamine can be decreased when it is combined with Magnesium ascorbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09480</drugbank-id>
      <name>Iofetamine I-123</name>
      <description>The serum concentration of Iofetamine I-123 can be decreased when it is combined with Magnesium ascorbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12080</drugbank-id>
      <name>Ritobegron</name>
      <description>The serum concentration of Ritobegron can be decreased when it is combined with Magnesium ascorbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13108</drugbank-id>
      <name>Mephedrone</name>
      <description>The serum concentration of Mephedrone can be decreased when it is combined with Magnesium ascorbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13624</drugbank-id>
      <name>Methoxyphenamine</name>
      <description>The serum concentration of Methoxyphenamine can be decreased when it is combined with Magnesium ascorbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13703</drugbank-id>
      <name>Gepefrine</name>
      <description>The serum concentration of Gepefrine can be decreased when it is combined with Magnesium ascorbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13940</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylthioamphetamine</name>
      <description>The serum concentration of 2,5-Dimethoxy-4-ethylthioamphetamine can be decreased when it is combined with Magnesium ascorbate.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-1.7</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-1.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>9.07e+00 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-1.9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>magnesium(2+) bis((2R)-2-[(1S)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2,5-dihydrofuran-3-olate)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>magnesium(2+) bis(vitamin-C)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>374.537</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>374.03356759</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[Mg++].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO.[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C12H14MgO12</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/2C6H8O6.Mg/c2*7-1-2(8)5-3(9)4(10)6(11)12-5;/h2*2,5,7-10H,1H2;/q;;+2/p-2/t2*2-,5+;/m00./s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>AIOKQVJVNPDJKA-ZZMNMWMASA-L</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>110.05</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>47.58</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>14.53</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>4.36</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>4934</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>17339241</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Magnesium_ascorbate</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>